A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3‐kinase/v‐akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma
What's known on the subject? and What does the study add? A few published studies investigating single or various PI3K/AKT/mTOR signalling components have produced inconsistent results. Moreover, PI3K regulatory subunit p85a and activated p70S6K expression levels have not been previously examin...
Saved in:
| Published in: | BJU international Vol. 110; no. 11c; pp. E1237 - E1248 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Oxford, UK
Blackwell Publishing Ltd
01.12.2012
Wiley Subscription Services, Inc |
| Subjects: | |
| ISSN: | 1464-4096, 1464-410X, 1464-410X |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | What's known on the subject? and What does the study add?
A few published studies investigating single or various PI3K/AKT/mTOR signalling components have produced inconsistent results. Moreover, PI3K regulatory subunit p85a and activated p70S6K expression levels have not been previously examined in urothelial carcinoma (UC).
The present study addresses simultaneously all key members of PI3K/AKT/mTOR signalling cascade supporting a differential implication of PI3K/AKT/mTOR pathway components in urothelial tumorigenesis. Furthermore, we propose p‐4E‐BP1 as a potential prognostic marker in UC, which might assist the selection of patients more likely to benefit from chemotherapy regimens based on PI3K/AKT/mTOR pathway inhibition. Finally, the present study indicates PIK3CA/AKT1 mutational status as a potential predictive marker for time‐to‐recurrence.
OBJECTIVE
•
To perform a comprehensive simultaneous assessment of all key members of phosphoinositide 3‐kinase/v‐akt murine thymoma viral oncogene/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway along with AKT homolog 1 (AKT1) and PIK3 catalytic alpha polypeptide (PIK3CA) mutations in bladder urothelial carcinoma (UC).
•
Published information is limited to a few studies looking into single or various combinations of members of this pathway with inconsistent results. In particular the expression status of phosphorylated (p‐)p70S6 kinase (p70S6K) and p85a subunit of PI3K has not been tested in UC.
PATIENTS AND METHODS
•
Paraffin‐embedded transurethral resection tissue from 113 patients with UC was investigated for the association of p85aPI3K, p‐AKT, p‐mTOR, p‐p70S6K and p‐4E‐BP1 (eukaryotic initiation factor 4E‐binding protein 1) expression status, as well as PIK3CA and AKT1 mutations with p‐extracellular signal‐regulated kinase 1/2 (ERK1/2), fibroblast growth factor receptor 3 (FGFR3), pathological features, recurrence and cancer‐specific survival.
RESULTS
•
With the exception of p‐p70S6K, all others components of the PI3K/AKT/mTOR pathway were upregulated in UCs as compared with normal urothelium.
•
p‐mTOR expression strongly correlated with its upstream p‐AKT and marginally with its downstream p‐p70S6K. p85aPI3K and p‐ERK1/2 levels were also marginally correlated.
•
PIK3CA and AKT1 mutations were distinctly uncommon and mutually exclusive, without any association with pathological features. However, the presence of AKT1 mutations was associated with increased FGFR3 levels and was restricted to p85aPI3K immunonegative cases, whereas PIK3CA mutant cases had marginally lower p85aPI3K levels.
•
The presence of PIK3CA single or combined with AKT1 mutations was associated with shorter recurrence‐free survival in univariate survival analysis. An inverse relationship was established between p‐4E‐BP1 immunopositivity and histological grade or T category, as well as between p‐p70S6K levels and T category, the latter relationship being of marginal significance.
•
p‐4E‐BP1 nuclear expression was marginally associated with the presence of lymphovascular invasion and adversely affected survival in multivariate, but not in univariate analysis.
CONCLUSIONS
•
PI3K/AKT/mTOR signalling components appear to be differentially implicated in urothelial tumorigenesis and, with the exception of p85aPI3K, are unrelated to the PIK3CA or AKT1 mutational status.
•
Our findings propose p‐4E‐BP1 as a potential prognostic marker in UC independent of its association with pathological features, which might assist the selection of patients more likely to benefit from PI3K/AKT/mTOR axis inhibition.
•
PIK3CA/AKT1 mutational status may have a place in the prediction of time‐to‐recurrence. |
|---|---|
| AbstractList | What's known on the subject? and What does the study add? A few published studies investigating single or various PI3K/AKT/mTOR signalling components have produced inconsistent results. Moreover, PI3K regulatory subunit p85a and activated p70S6K expression levels have not been previously examined in urothelial carcinoma (UC). The present study addresses simultaneously all key members of PI3K/AKT/mTOR signalling cascade supporting a differential implication of PI3K/AKT/mTOR pathway components in urothelial tumorigenesis. Furthermore, we propose p-4E-BP1 as a potential prognostic marker in UC, which might assist the selection of patients more likely to benefit from chemotherapy regimens based on PI3K/AKT/mTOR pathway inhibition. Finally, the present study indicates PIK3CA/AKT1 mutational status as a potential predictive marker for time-to-recurrence. times To perform a comprehensive simultaneous assessment of all key members of phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway along with AKT homolog 1 (AKT1) and PIK3 catalytic alpha polypeptide (PIK3CA) mutations in bladder urothelial carcinoma (UC). times Paraffin-embedded transurethral resection tissue from 113 patients with UC was investigated for the association of p85aPI3K, p-AKT, p-mTOR, p-p70S6K and p-4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) expression status, as well as PIK3CA and AKT1 mutations with p-extracellular signal-regulated kinase 1/2 (ERK1/2), fibroblast growth factor receptor 3 (FGFR3), pathological features, recurrence and cancer-specific survival. times With the exception of p-p70S6K, all others components of the PI3K/AKT/mTOR pathway were upregulated in UCs as compared with normal urothelium. times PI3K/AKT/mTOR signalling components appear to be differentially implicated in urothelial tumorigenesis and, with the exception of p85aPI3K, are unrelated to the PIK3CA or AKT1 mutational status. What's known on the subject? and What does the study add? A few published studies investigating single or various PI3K/AKT/mTOR signalling components have produced inconsistent results. Moreover, PI3K regulatory subunit p85a and activated p70S6K expression levels have not been previously examined in urothelial carcinoma (UC). The present study addresses simultaneously all key members of PI3K/AKT/mTOR signalling cascade supporting a differential implication of PI3K/AKT/mTOR pathway components in urothelial tumorigenesis. Furthermore, we propose p‐4E‐BP1 as a potential prognostic marker in UC, which might assist the selection of patients more likely to benefit from chemotherapy regimens based on PI3K/AKT/mTOR pathway inhibition. Finally, the present study indicates PIK3CA/AKT1 mutational status as a potential predictive marker for time‐to‐recurrence. OBJECTIVE • To perform a comprehensive simultaneous assessment of all key members of phosphoinositide 3‐kinase/v‐akt murine thymoma viral oncogene/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway along with AKT homolog 1 (AKT1) and PIK3 catalytic alpha polypeptide (PIK3CA) mutations in bladder urothelial carcinoma (UC). • Published information is limited to a few studies looking into single or various combinations of members of this pathway with inconsistent results. In particular the expression status of phosphorylated (p‐)p70S6 kinase (p70S6K) and p85a subunit of PI3K has not been tested in UC. PATIENTS AND METHODS • Paraffin‐embedded transurethral resection tissue from 113 patients with UC was investigated for the association of p85aPI3K, p‐AKT, p‐mTOR, p‐p70S6K and p‐4E‐BP1 (eukaryotic initiation factor 4E‐binding protein 1) expression status, as well as PIK3CA and AKT1 mutations with p‐extracellular signal‐regulated kinase 1/2 (ERK1/2), fibroblast growth factor receptor 3 (FGFR3), pathological features, recurrence and cancer‐specific survival. RESULTS • With the exception of p‐p70S6K, all others components of the PI3K/AKT/mTOR pathway were upregulated in UCs as compared with normal urothelium. • p‐mTOR expression strongly correlated with its upstream p‐AKT and marginally with its downstream p‐p70S6K. p85aPI3K and p‐ERK1/2 levels were also marginally correlated. • PIK3CA and AKT1 mutations were distinctly uncommon and mutually exclusive, without any association with pathological features. However, the presence of AKT1 mutations was associated with increased FGFR3 levels and was restricted to p85aPI3K immunonegative cases, whereas PIK3CA mutant cases had marginally lower p85aPI3K levels. • The presence of PIK3CA single or combined with AKT1 mutations was associated with shorter recurrence‐free survival in univariate survival analysis. An inverse relationship was established between p‐4E‐BP1 immunopositivity and histological grade or T category, as well as between p‐p70S6K levels and T category, the latter relationship being of marginal significance. • p‐4E‐BP1 nuclear expression was marginally associated with the presence of lymphovascular invasion and adversely affected survival in multivariate, but not in univariate analysis. CONCLUSIONS • PI3K/AKT/mTOR signalling components appear to be differentially implicated in urothelial tumorigenesis and, with the exception of p85aPI3K, are unrelated to the PIK3CA or AKT1 mutational status. • Our findings propose p‐4E‐BP1 as a potential prognostic marker in UC independent of its association with pathological features, which might assist the selection of patients more likely to benefit from PI3K/AKT/mTOR axis inhibition. • PIK3CA/AKT1 mutational status may have a place in the prediction of time‐to‐recurrence. What's known on the subject? and What does the study add? A few published studies investigating single or various PI3K/AKT/mTOR signalling components have produced inconsistent results. Moreover, PI3K regulatory subunit p85a and activated p70S6K expression levels have not been previously examined in urothelial carcinoma (UC). The present study addresses simultaneously all key members of PI3K/AKT/mTOR signalling cascade supporting a differential implication of PI3K/AKT/mTOR pathway components in urothelial tumorigenesis. Furthermore, we propose p-4E-BP1 as a potential prognostic marker in UC, which might assist the selection of patients more likely to benefit from chemotherapy regimens based on PI3K/AKT/mTOR pathway inhibition. Finally, the present study indicates PIK3CA/AKT1 mutational status as a potential predictive marker for time-to-recurrence.UNLABELLEDWhat's known on the subject? and What does the study add? A few published studies investigating single or various PI3K/AKT/mTOR signalling components have produced inconsistent results. Moreover, PI3K regulatory subunit p85a and activated p70S6K expression levels have not been previously examined in urothelial carcinoma (UC). The present study addresses simultaneously all key members of PI3K/AKT/mTOR signalling cascade supporting a differential implication of PI3K/AKT/mTOR pathway components in urothelial tumorigenesis. Furthermore, we propose p-4E-BP1 as a potential prognostic marker in UC, which might assist the selection of patients more likely to benefit from chemotherapy regimens based on PI3K/AKT/mTOR pathway inhibition. Finally, the present study indicates PIK3CA/AKT1 mutational status as a potential predictive marker for time-to-recurrence.• To perform a comprehensive simultaneous assessment of all key members of phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway along with AKT homolog 1 (AKT1) and PIK3 catalytic alpha polypeptide (PIK3CA) mutations in bladder urothelial carcinoma (UC). • Published information is limited to a few studies looking into single or various combinations of members of this pathway with inconsistent results. In particular the expression status of phosphorylated (p-)p70S6 kinase (p70S6K) and p85a subunit of PI3K has not been tested in UC.OBJECTIVE• To perform a comprehensive simultaneous assessment of all key members of phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway along with AKT homolog 1 (AKT1) and PIK3 catalytic alpha polypeptide (PIK3CA) mutations in bladder urothelial carcinoma (UC). • Published information is limited to a few studies looking into single or various combinations of members of this pathway with inconsistent results. In particular the expression status of phosphorylated (p-)p70S6 kinase (p70S6K) and p85a subunit of PI3K has not been tested in UC.• Paraffin-embedded transurethral resection tissue from 113 patients with UC was investigated for the association of p85aPI3K, p-AKT, p-mTOR, p-p70S6K and p-4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) expression status, as well as PIK3CA and AKT1 mutations with p-extracellular signal-regulated kinase 1/2 (ERK1/2), fibroblast growth factor receptor 3 (FGFR3), pathological features, recurrence and cancer-specific survival.PATIENTS AND METHODS• Paraffin-embedded transurethral resection tissue from 113 patients with UC was investigated for the association of p85aPI3K, p-AKT, p-mTOR, p-p70S6K and p-4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) expression status, as well as PIK3CA and AKT1 mutations with p-extracellular signal-regulated kinase 1/2 (ERK1/2), fibroblast growth factor receptor 3 (FGFR3), pathological features, recurrence and cancer-specific survival.• With the exception of p-p70S6K, all others components of the PI3K/AKT/mTOR pathway were upregulated in UCs as compared with normal urothelium. • p-mTOR expression strongly correlated with its upstream p-AKT and marginally with its downstream p-p70S6K. p85aPI3K and p-ERK1/2 levels were also marginally correlated. • PIK3CA and AKT1 mutations were distinctly uncommon and mutually exclusive, without any association with pathological features. However, the presence of AKT1 mutations was associated with increased FGFR3 levels and was restricted to p85aPI3K immunonegative cases, whereas PIK3CA mutant cases had marginally lower p85aPI3K levels. • The presence of PIK3CA single or combined with AKT1 mutations was associated with shorter recurrence-free survival in univariate survival analysis. An inverse relationship was established between p-4E-BP1 immunopositivity and histological grade or T category, as well as between p-p70S6K levels and T category, the latter relationship being of marginal significance. • p-4E-BP1 nuclear expression was marginally associated with the presence of lymphovascular invasion and adversely affected survival in multivariate, but not in univariate analysis.RESULTS• With the exception of p-p70S6K, all others components of the PI3K/AKT/mTOR pathway were upregulated in UCs as compared with normal urothelium. • p-mTOR expression strongly correlated with its upstream p-AKT and marginally with its downstream p-p70S6K. p85aPI3K and p-ERK1/2 levels were also marginally correlated. • PIK3CA and AKT1 mutations were distinctly uncommon and mutually exclusive, without any association with pathological features. However, the presence of AKT1 mutations was associated with increased FGFR3 levels and was restricted to p85aPI3K immunonegative cases, whereas PIK3CA mutant cases had marginally lower p85aPI3K levels. • The presence of PIK3CA single or combined with AKT1 mutations was associated with shorter recurrence-free survival in univariate survival analysis. An inverse relationship was established between p-4E-BP1 immunopositivity and histological grade or T category, as well as between p-p70S6K levels and T category, the latter relationship being of marginal significance. • p-4E-BP1 nuclear expression was marginally associated with the presence of lymphovascular invasion and adversely affected survival in multivariate, but not in univariate analysis.• PI3K/AKT/mTOR signalling components appear to be differentially implicated in urothelial tumorigenesis and, with the exception of p85aPI3K, are unrelated to the PIK3CA or AKT1 mutational status. • Our findings propose p-4E-BP1 as a potential prognostic marker in UC independent of its association with pathological features, which might assist the selection of patients more likely to benefit from PI3K/AKT/mTOR axis inhibition. • PIK3CA/AKT1 mutational status may have a place in the prediction of time-to-recurrence.CONCLUSIONS• PI3K/AKT/mTOR signalling components appear to be differentially implicated in urothelial tumorigenesis and, with the exception of p85aPI3K, are unrelated to the PIK3CA or AKT1 mutational status. • Our findings propose p-4E-BP1 as a potential prognostic marker in UC independent of its association with pathological features, which might assist the selection of patients more likely to benefit from PI3K/AKT/mTOR axis inhibition. • PIK3CA/AKT1 mutational status may have a place in the prediction of time-to-recurrence. What's known on the subject? and What does the study add? A few published studies investigating single or various PI3K/AKT/mTOR signalling components have produced inconsistent results. Moreover, PI3K regulatory subunit p85a and activated p70S6K expression levels have not been previously examined in urothelial carcinoma (UC). The present study addresses simultaneously all key members of PI3K/AKT/mTOR signalling cascade supporting a differential implication of PI3K/AKT/mTOR pathway components in urothelial tumorigenesis. Furthermore, we propose p-4E-BP1 as a potential prognostic marker in UC, which might assist the selection of patients more likely to benefit from chemotherapy regimens based on PI3K/AKT/mTOR pathway inhibition. Finally, the present study indicates PIK3CA/AKT1 mutational status as a potential predictive marker for time-to-recurrence. OBJECTIVE * To perform a comprehensive simultaneous assessment of all key members of phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway along with AKT homolog 1 (AKT1) and PIK3 catalytic alpha polypeptide (PIK3CA) mutations in bladder urothelial carcinoma (UC). * Published information is limited to a few studies looking into single or various combinations of members of this pathway with inconsistent results. In particular the expression status of phosphorylated (p-)p70S6 kinase (p70S6K) and p85a subunit of PI3K has not been tested in UC. PATIENTS AND METHODS * Paraffin-embedded transurethral resection tissue from 113 patients with UC was investigated for the association of p85aPI3K, p-AKT, p-mTOR, p-p70S6K and p-4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) expression status, as well as PIK3CA and AKT1 mutations with p-extracellular signal-regulated kinase 1/2 (ERK1/2), fibroblast growth factor receptor 3(FGFR3), pathological features, recurrence and cancer-specific survival. RESULTS * With the exception of p-p70S6K, all others components of the PI3K/AKT/mTOR pathway were upregulated in UCs as compared with normal urothelium. * p-mTOR expression strongly correlated with its upstream p-AKT and marginally with its downstream p-p70S6K. p85aPI3K and p-ERK1/2 levels were also marginally correlated. * PIK3CA and AKT1 mutations were distinctly uncommon and mutually exclusive, without any association with pathological features. However, the presence of AKT1 mutations was associated with increased FGFR3 levels and was restricted to p85aPI3K immunonegative cases, whereas PIK3CA mutant cases had marginally lower p85aPI3K levels. * The presence of PIK3CA single or combined with AKT1 mutations was associated with shorter recurrence-free survival in univariate survival analysis. An inverse relationship was established between p-4E-BP1 immunopositivity and histological grade or T category, as well as between p-p70S6K levels and T category, the latter relationship being of marginal significance. * p-4E-BP1 nuclear expression was marginally associated with the presence of lymphovascular invasion and adversely affected survival in multivariate, but not in univariate analysis. CONCLUSIONS * PI3K/AKT/mTOR signalling components appear to be differentially implicated in urothelial tumorigenesis and, with the exception of p85aPI3K, are unrelated to the PIK3CA or AKT1 mutational status. * Our findings propose p-4E-BP1 as a potential prognostic marker in UC independent of its association with pathological features, which might assist the selection of patients more likely to benefit from PI3K/AKT/mTOR axis inhibition. * PIK3CA/AKT1 mutational status may have a place in the prediction of time-to-recurrence. What's known on the subject? and What does the study add? A few published studies investigating single or various PI3K/AKT/mTOR signalling components have produced inconsistent results. Moreover, PI3K regulatory subunit p85a and activated p70S6K expression levels have not been previously examined in urothelial carcinoma (UC). The present study addresses simultaneously all key members of PI3K/AKT/mTOR signalling cascade supporting a differential implication of PI3K/AKT/mTOR pathway components in urothelial tumorigenesis. Furthermore, we propose p-4E-BP1 as a potential prognostic marker in UC, which might assist the selection of patients more likely to benefit from chemotherapy regimens based on PI3K/AKT/mTOR pathway inhibition. Finally, the present study indicates PIK3CA/AKT1 mutational status as a potential predictive marker for time-to-recurrence. • To perform a comprehensive simultaneous assessment of all key members of phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway along with AKT homolog 1 (AKT1) and PIK3 catalytic alpha polypeptide (PIK3CA) mutations in bladder urothelial carcinoma (UC). • Published information is limited to a few studies looking into single or various combinations of members of this pathway with inconsistent results. In particular the expression status of phosphorylated (p-)p70S6 kinase (p70S6K) and p85a subunit of PI3K has not been tested in UC. • Paraffin-embedded transurethral resection tissue from 113 patients with UC was investigated for the association of p85aPI3K, p-AKT, p-mTOR, p-p70S6K and p-4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) expression status, as well as PIK3CA and AKT1 mutations with p-extracellular signal-regulated kinase 1/2 (ERK1/2), fibroblast growth factor receptor 3 (FGFR3), pathological features, recurrence and cancer-specific survival. • With the exception of p-p70S6K, all others components of the PI3K/AKT/mTOR pathway were upregulated in UCs as compared with normal urothelium. • p-mTOR expression strongly correlated with its upstream p-AKT and marginally with its downstream p-p70S6K. p85aPI3K and p-ERK1/2 levels were also marginally correlated. • PIK3CA and AKT1 mutations were distinctly uncommon and mutually exclusive, without any association with pathological features. However, the presence of AKT1 mutations was associated with increased FGFR3 levels and was restricted to p85aPI3K immunonegative cases, whereas PIK3CA mutant cases had marginally lower p85aPI3K levels. • The presence of PIK3CA single or combined with AKT1 mutations was associated with shorter recurrence-free survival in univariate survival analysis. An inverse relationship was established between p-4E-BP1 immunopositivity and histological grade or T category, as well as between p-p70S6K levels and T category, the latter relationship being of marginal significance. • p-4E-BP1 nuclear expression was marginally associated with the presence of lymphovascular invasion and adversely affected survival in multivariate, but not in univariate analysis. • PI3K/AKT/mTOR signalling components appear to be differentially implicated in urothelial tumorigenesis and, with the exception of p85aPI3K, are unrelated to the PIK3CA or AKT1 mutational status. • Our findings propose p-4E-BP1 as a potential prognostic marker in UC independent of its association with pathological features, which might assist the selection of patients more likely to benefit from PI3K/AKT/mTOR axis inhibition. • PIK3CA/AKT1 mutational status may have a place in the prediction of time-to-recurrence. |
| Author | Sakellariou, Stratigoula Fragkou, Paraskevi Patsouris, Efstratios Pavlopoulos, Petros Saetta, Angelica A. Levidou, Georgia Thymara, Irene Isaiadis, Dimitrios Trigka, Eleni‐Andriana Korkolopoulou, Penelope Prekete, Niki Karlou, Maria |
| Author_xml | – sequence: 1 givenname: Penelope surname: Korkolopoulou fullname: Korkolopoulou, Penelope – sequence: 2 givenname: Georgia surname: Levidou fullname: Levidou, Georgia – sequence: 3 givenname: Eleni‐Andriana surname: Trigka fullname: Trigka, Eleni‐Andriana – sequence: 4 givenname: Niki surname: Prekete fullname: Prekete, Niki – sequence: 5 givenname: Maria surname: Karlou fullname: Karlou, Maria – sequence: 6 givenname: Irene surname: Thymara fullname: Thymara, Irene – sequence: 7 givenname: Stratigoula surname: Sakellariou fullname: Sakellariou, Stratigoula – sequence: 8 givenname: Paraskevi surname: Fragkou fullname: Fragkou, Paraskevi – sequence: 9 givenname: Dimitrios surname: Isaiadis fullname: Isaiadis, Dimitrios – sequence: 10 givenname: Petros surname: Pavlopoulos fullname: Pavlopoulos, Petros – sequence: 11 givenname: Efstratios surname: Patsouris fullname: Patsouris, Efstratios – sequence: 12 givenname: Angelica A. surname: Saetta fullname: Saetta, Angelica A. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23107319$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUstuEzEUHaEi-oBfQJbYlEUS2_PeIIWKR2mlIpRK7Kw7njsdp2N7as-kzY5P4PfY8iU4bcKiq1iyfHV9Hn6c4-jAWINRRBidsjBmyylLsmSSMPpzyinjoZtm5fThRXT0f-NgV9MyO4yOvV9SGhpZ-io65DGjeczKo-jPnEire4ctGq9WSJTWo7Gt8oOVLWoloSNgaqJth3LswBHoe2dBtmSwZGiRfD-PL2bzi8VML65-kNO-tT5MZaxXg6qRxH9__b5VBjzOVqGE24Ho0SmDgb3WVgNZKRdcrJH2Bg3ONGgNnQJDBnA3OBDbEAc96LVU5j3pYWjvYU2UIVUHdY2OjM6GkwRKRyS4gAqqr6OXDXQe32zXk-j686fF2dfJ5dWX87P55UQmZV5O6pSWSc4LTKoqr0usmjRNS14wRmOOTVXUVZrETUMLqHjNsciTNKFYQZ5ndVbT-CQ6fdINr3I3oh-EVl5i14FBO3rBeBEsMs73gYZP4QWPswB99wy6tKMz4SKC5VleJhmjZUC93aLGSmMteqc0uLXY_W8AfHgCSGe9d9gIqQYYlDWDA9UJRsUmUGIpNlkRm9yITaDEY6DEQxAongnsPPagbr3vVYfrvXni47frxzL-B4vi6IM |
| CODEN | BJINFO |
| CitedBy_id | crossref_primary_10_3390_jpm13040673 crossref_primary_10_1155_2022_1720851 crossref_primary_10_1007_s00428_016_1938_5 crossref_primary_10_3109_10408363_2015_1033610 crossref_primary_10_1111_apm_12398 crossref_primary_10_4081_ejh_2021_3304 crossref_primary_10_1007_s00428_014_1641_3 crossref_primary_10_1038_cddis_2014_79 crossref_primary_10_1111_cpr_12815 crossref_primary_10_1002_path_4334 crossref_primary_10_1002_ijc_29140 crossref_primary_10_1007_s12253_016_0056_7 crossref_primary_10_3892_or_2013_2512 crossref_primary_10_3389_fonc_2020_588200 crossref_primary_10_2174_1381612825666190110143258 crossref_primary_10_3892_ol_2014_2392 crossref_primary_10_1158_1541_7786_MCR_18_0923 crossref_primary_10_1111_acel_12242 crossref_primary_10_1007_s13277_015_4678_2 crossref_primary_10_1016_j_tranon_2016_07_007 crossref_primary_10_1371_journal_pone_0141253 crossref_primary_10_1371_journal_pone_0133859 crossref_primary_10_3390_cancers14133183 crossref_primary_10_1016_j_juro_2017_06_096 crossref_primary_10_1002_mc_22125 crossref_primary_10_1186_1471_2407_13_602 crossref_primary_10_1016_j_prp_2016_02_008 crossref_primary_10_1016_j_jaad_2013_04_027 crossref_primary_10_3892_ijo_2015_2995 crossref_primary_10_1158_0008_5472_CAN_14_1218 crossref_primary_10_3389_fonc_2022_1016542 crossref_primary_10_1016_j_urolonc_2014_02_003 crossref_primary_10_3892_or_2013_2944 crossref_primary_10_3390_ijms21145002 crossref_primary_10_14694_EdBook_AM_2015_35_105 crossref_primary_10_1016_j_urolonc_2013_06_009 crossref_primary_10_1016_j_pharmthera_2014_06_004 crossref_primary_10_1016_j_gene_2018_09_022 crossref_primary_10_1016_j_biopha_2017_05_037 crossref_primary_10_3390_vetsci10030201 crossref_primary_10_1002_2211_5463_12583 |
| Cites_doi | 10.1002/path.2207 10.1016/j.ceb.2005.09.009 10.1111/j.1365-2559.2011.03856.x 10.1016/j.cancergencyto.2009.01.009 10.1158/0008-5472.CAN-09-3399 10.1016/j.urology.2008.09.070 10.4161/cbt.8.24.9987 10.1038/sj.onc.1210422 10.1038/onc.2009.315 10.1371/journal.pone.0018583 10.1038/nrc1819 10.1002/cncr.25502 10.1158/0008-5472.CAN-06-0364 10.1038/onc.2009.280 10.2353/ajpath.2010.090872 10.1158/1940-6207.CAPR-09-0169 10.1111/j.1464-410X.2010.09517.x 10.1016/j.humpath.2011.10.026 10.1158/1535-7163.MCT-10-0413 10.1016/j.urolonc.2010.04.008 10.1158/1078-0432.CCR-06-1560 10.1038/345544a0 10.1016/j.ccr.2010.05.023 10.1016/j.ccr.2004.05.024 10.1101/gad.1772909 10.1111/j.1464-410X.2004.04574.x 10.1111/j.1464-410X.2010.09844.x 10.1126/science.1135394 10.1073/pnas.0712169105 10.1016/j.ccr.2007.05.008 10.1038/nature04869 10.1080/00313020902885011 10.1074/jbc.M501707200 10.1111/j.1365-2559.2012.04236.x 10.1128/MCB.24.8.3112-3124.2004 10.1023/A:1022943419011 10.1128/MCB.18.3.1379 10.1111/j.1464-410X.2009.08538.x 10.1101/gad.1212704 10.1158/0008-5472.CAN-07-0881 10.1074/jbc.M512218200 10.4111/kju.2011.52.7.466 |
| ContentType | Journal Article |
| Copyright | 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. BJUI © 2012 BJU International |
| Copyright_xml | – notice: 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL – notice: 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. – notice: BJUI © 2012 BJU International |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7X8 7TO 7U9 H94 |
| DOI | 10.1111/j.1464-410X.2012.11569.x |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts MEDLINE - Academic Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Calcium & Calcified Tissue Abstracts MEDLINE - Academic Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts Virology and AIDS Abstracts |
| DatabaseTitleList | Oncogenes and Growth Factors Abstracts MEDLINE - Academic Calcium & Calcified Tissue Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-410X |
| EndPage | E1248 |
| ExternalDocumentID | 3963142731 23107319 10_1111_j_1464_410X_2012_11569_x BJU11569 |
| Genre | article Journal Article Comparative Study |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OB 1OC 23N 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACUHS ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFNX AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AIQQE AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HF~ HGLYW HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K RJQFR ROL RX1 SUPJJ SV3 TEORI TUS UB1 V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ~IA ~WT AAYXX CITATION O8X AAHHS ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CGR CUY CVF ECM EIF NPM 7QP 7X8 7TO 7U9 H94 |
| ID | FETCH-LOGICAL-c4979-d5094728e4bb7d9ebf55592811032efb8db543ff08ab2d2e874540eba776d6d03 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 49 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000315029700075&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1464-4096 1464-410X |
| IngestDate | Wed Oct 01 14:38:56 EDT 2025 Thu Oct 02 14:38:41 EDT 2025 Sat Nov 29 14:22:25 EST 2025 Thu Apr 03 07:00:38 EDT 2025 Tue Nov 18 21:14:48 EST 2025 Sat Nov 29 06:59:27 EST 2025 Sun Sep 21 06:18:25 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11c |
| Language | English |
| License | 2012 THE AUTHORS. BJU INTERNATIONAL © 2012 BJU INTERNATIONAL. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4979-d5094728e4bb7d9ebf55592811032efb8db543ff08ab2d2e874540eba776d6d03 |
| Notes | P.K., G.L., E‐A.T. and N.P. contributed equally to the manuscript ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| PMID | 23107319 |
| PQID | 1767946109 |
| PQPubID | 1026371 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_1285096220 proquest_miscellaneous_1273128236 proquest_journals_1767946109 pubmed_primary_23107319 crossref_citationtrail_10_1111_j_1464_410X_2012_11569_x crossref_primary_10_1111_j_1464_410X_2012_11569_x wiley_primary_10_1111_j_1464_410X_2012_11569_x_BJU11569 |
| PublicationCentury | 2000 |
| PublicationDate | December 2012 |
| PublicationDateYYYYMMDD | 2012-12-01 |
| PublicationDate_xml | – month: 12 year: 2012 text: December 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: England – name: Edgecliff |
| PublicationTitle | BJU international |
| PublicationTitleAlternate | BJU Int |
| PublicationYear | 2012 |
| Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
| References | 2012; 61 2009; 23 2009; 41 1990; 345 2010; 18 2004; 24 2011; 52 2006; 6 2004; 5 2008; 105 2004 2011; 58 2011; 6 2007; 12 2007; 13 2009; 28 2007; 213 1998; 18 2005; 280 2007; 317 2011; 108 2009; 73 2011; 107 2004; 93 2004; 18 2009; 191 2010; 116 2010; 29 2010; 28 2006; 66 2010; 176 2009; 8 2006; 281 2010; 70 2009; 2 2005; 17 2007; 67 2012; 43 2003; 20 2009; 104 2006; 441 2007; 26 2010; 9 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_9_2 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_18_2 e_1_2_7_17_2 Eble JN (e_1_2_7_13_2) 2004 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_40_2 e_1_2_7_41_2 e_1_2_7_12_2 e_1_2_7_42_2 e_1_2_7_11_2 e_1_2_7_43_2 e_1_2_7_10_2 e_1_2_7_44_2 e_1_2_7_26_2 e_1_2_7_27_2 e_1_2_7_28_2 e_1_2_7_29_2 e_1_2_7_25_2 e_1_2_7_24_2 e_1_2_7_30_2 e_1_2_7_23_2 e_1_2_7_31_2 e_1_2_7_22_2 e_1_2_7_32_2 e_1_2_7_21_2 e_1_2_7_33_2 e_1_2_7_20_2 e_1_2_7_34_2 e_1_2_7_35_2 e_1_2_7_36_2 e_1_2_7_37_2 e_1_2_7_38_2 e_1_2_7_39_2 |
| References_xml | – volume: 70 start-page: 5305 year: 2010 end-page: 15 article-title: The phosphoinositide 3‐kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling publication-title: Cancer Res – volume: 213 start-page: 91 year: 2007 end-page: 8 article-title: FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer publication-title: J Pathol – volume: 116 start-page: 5517 year: 2010 end-page: 26 article-title: Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy publication-title: Cancer – volume: 6 start-page: 184 year: 2006 end-page: 92 article-title: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis publication-title: Nat Rev Cancer – volume: 43 start-page: 1573 year: 2012 end-page: 82 article-title: Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer publication-title: Hum Pathol – volume: 281 start-page: 7357 year: 2006 end-page: 63 article-title: A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1 publication-title: J Biol Chem – volume: 9 start-page: 3158 year: 2010 end-page: 63 article-title: Modulation of 4E‐BP1 function as a critical determinant of enzastaurin‐induced apoptosis publication-title: Mol Cancer Ther – volume: 28 start-page: 4306 year: 2009 end-page: 16 article-title: Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type‐ and mutation‐specific manner publication-title: Oncogene – volume: 107 start-page: 844 year: 2011 end-page: 9 article-title: Hypoxia‐inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications publication-title: BJU Int – volume: 8 start-page: 2339 year: 2009 end-page: 47 article-title: Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer publication-title: Cancer Biol Ther – volume: 104 start-page: 1009 year: 2009 end-page: 16 article-title: Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics publication-title: BJU Int – volume: 441 start-page: 424 year: 2006 end-page: 30 article-title: Ras, PI(3)K and mTOR signalling controls tumour cell growth publication-title: Nature – volume: 108 start-page: E84 year: 2011 end-page: 90 article-title: The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers publication-title: BJU Int – volume: 18 start-page: 39 year: 2010 end-page: 51 article-title: 4E‐BP1 is a key effector of the oncogenic activation of the AKT and ERK signalling pathways that intergrates their function in tumours publication-title: Cancer Cell – volume: 5 start-page: 553 year: 2004 end-page: 63 article-title: Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells publication-title: Cancer Cell – volume: 58 start-page: 1054 year: 2011 end-page: 63 article-title: Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder publication-title: Histopathology – volume: 18 start-page: 1379 year: 1998 end-page: 87 article-title: Regulation of the p85/p110 phosphatidylinositol 3′‐kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit publication-title: Mol Cell Biol – volume: 317 start-page: 239 year: 2007 end-page: 42 article-title: Mechanism of two classes of cancer mutations in the phosphoinositide 3‐kinase catalytic subunit publication-title: Science – volume: 61 start-page: 293 year: 2012 end-page: 305 article-title: Phosphorylated 4E‐binding protein 1 (p‐4E‐BP1): a novel prognostic marker in human astrocytomas publication-title: Histopathology – volume: 52 start-page: 466 year: 2011 end-page: 73 article-title: Role of the mTOR pathway in the progression and recurrence of bladder cancer: an immunohistochemical tissue microarray study publication-title: Korean J Urol – volume: 29 start-page: 150 year: 2010 end-page: 5 article-title: AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co‐operate with E17K publication-title: Oncogene – volume: 105 start-page: 2652 year: 2008 end-page: 7 article-title: Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3‐kinase induce gain of function by different mechanisms publication-title: Proc Natl Acad Sci USA – volume: 66 start-page: 5618 year: 2006 end-page: 23 article-title: AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signalling publication-title: Cancer Res – volume: 93 start-page: 143 year: 2004 end-page: 50 article-title: The phosphatidylinositol‐3 kinase pathway regulates bladder cancer cell invasion publication-title: BJU Int – volume: 73 start-page: 665 year: 2009 end-page: 9 article-title: Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer publication-title: Urology – volume: 280 start-page: 25485 year: 2005 end-page: 90 article-title: Phosphorylation of mammalian target of rapamycin (mTOR) at Ser‐2448 is mediated by p70S6 kinase publication-title: J Biol Chem – volume: 26 start-page: 3291 year: 2007 end-page: 310 article-title: Targeting the Raf‐MEK‐ERK mitogen‐activated protein kinase cascade for the treatment of cancer publication-title: Oncogene – volume: 17 start-page: 596 year: 2005 end-page: 603 article-title: Growing roles for the mTOR pathway publication-title: Curr Opin Cell Biol – volume: 24 start-page: 3112 year: 2004 end-page: 24 article-title: S6K1(‐/‐)/S6K2(‐/‐) mice exhibit perinatal lethality and rapamycin‐sensitive 5′‐terminal oligopyrimidine mRNA translation and reveal a mitogen‐activated protein kinase‐dependent S6 kinase pathway publication-title: Mol Cell Biol – volume: 6 start-page: e18583 year: 2011 article-title: A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1 publication-title: PLoS ONE – volume: 20 start-page: 265 year: 2003 end-page: 73 article-title: Translational control and metastatic progression: enhanced activity of the mRNA cap‐binding protein eIF‐4E selectively enhances translation of metastasis‐related mRNAs publication-title: Clin Exp Metastasis – volume: 41 start-page: 327 year: 2009 end-page: 34 article-title: Activation of extracellular regulated kinases (ERK 1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B‐Raf gene mutations publication-title: Pathology – volume: 23 start-page: 675 year: 2009 end-page: 80 article-title: Inactivation of p53 and Pten promotes invasive bladder cancer publication-title: Genes Dev – volume: 28 start-page: 429 year: 2010 end-page: 40 article-title: Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression publication-title: Urol Oncol – volume: 191 start-page: 34 year: 2009 end-page: 7 article-title: AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma publication-title: Cancer Genet Cytogenet – volume: 67 start-page: 7551 year: 2007 end-page: 5 article-title: 4E‐binding protein 1: a key molecular ‘funnel factor’ in human cancer with clinical implications publication-title: Cancer Res – volume: 18 start-page: 1926 year: 2004 end-page: 45 article-title: Upstream and downstream of mTOR publication-title: Genes Dev – volume: 2 start-page: 1008 year: 2009 end-page: 14 article-title: Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer publication-title: Cancer Prev Res (Phila) – volume: 13 start-page: 81 year: 2007 end-page: 9 article-title: 4E‐binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis publication-title: Clin Cancer Res – volume: 176 start-page: 3062 year: 2010 end-page: 72 article-title: Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma publication-title: Am J Pathol – volume: 12 start-page: 9 year: 2007 end-page: 22 article-title: Defining the role of mTOR in cancer publication-title: Cancer Cell – volume: 345 start-page: 544 year: 1990 end-page: 7 article-title: Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap publication-title: Nature – start-page: 89 year: 2004 end-page: 115 – ident: e_1_2_7_11_2 doi: 10.1002/path.2207 – ident: e_1_2_7_4_2 doi: 10.1016/j.ceb.2005.09.009 – ident: e_1_2_7_23_2 doi: 10.1111/j.1365-2559.2011.03856.x – ident: e_1_2_7_26_2 doi: 10.1016/j.cancergencyto.2009.01.009 – ident: e_1_2_7_8_2 doi: 10.1158/0008-5472.CAN-09-3399 – ident: e_1_2_7_19_2 doi: 10.1016/j.urology.2008.09.070 – ident: e_1_2_7_22_2 doi: 10.4161/cbt.8.24.9987 – ident: e_1_2_7_37_2 doi: 10.1038/sj.onc.1210422 – ident: e_1_2_7_27_2 doi: 10.1038/onc.2009.315 – ident: e_1_2_7_28_2 doi: 10.1371/journal.pone.0018583 – ident: e_1_2_7_3_2 doi: 10.1038/nrc1819 – ident: e_1_2_7_25_2 doi: 10.1002/cncr.25502 – ident: e_1_2_7_31_2 doi: 10.1158/0008-5472.CAN-06-0364 – start-page: 89 volume-title: World Health Organization Classification of Tumours. Pathology and Genetics, Tumours of the Urinary System and Male Genital Track year: 2004 ident: e_1_2_7_13_2 – ident: e_1_2_7_9_2 doi: 10.1038/onc.2009.280 – ident: e_1_2_7_18_2 doi: 10.2353/ajpath.2010.090872 – ident: e_1_2_7_21_2 doi: 10.1158/1940-6207.CAPR-09-0169 – ident: e_1_2_7_20_2 doi: 10.1111/j.1464-410X.2010.09517.x – ident: e_1_2_7_10_2 doi: 10.1016/j.humpath.2011.10.026 – ident: e_1_2_7_43_2 doi: 10.1158/1535-7163.MCT-10-0413 – ident: e_1_2_7_2_2 doi: 10.1016/j.urolonc.2010.04.008 – ident: e_1_2_7_14_2 doi: 10.1158/1078-0432.CCR-06-1560 – ident: e_1_2_7_39_2 doi: 10.1038/345544a0 – ident: e_1_2_7_36_2 doi: 10.1016/j.ccr.2010.05.023 – ident: e_1_2_7_38_2 doi: 10.1016/j.ccr.2004.05.024 – ident: e_1_2_7_40_2 doi: 10.1101/gad.1772909 – ident: e_1_2_7_16_2 doi: 10.1111/j.1464-410X.2004.04574.x – ident: e_1_2_7_17_2 doi: 10.1111/j.1464-410X.2010.09844.x – ident: e_1_2_7_7_2 doi: 10.1126/science.1135394 – ident: e_1_2_7_29_2 doi: 10.1073/pnas.0712169105 – ident: e_1_2_7_35_2 doi: 10.1016/j.ccr.2007.05.008 – ident: e_1_2_7_34_2 doi: 10.1038/nature04869 – ident: e_1_2_7_12_2 doi: 10.1080/00313020902885011 – ident: e_1_2_7_32_2 doi: 10.1074/jbc.M501707200 – ident: e_1_2_7_15_2 doi: 10.1111/j.1365-2559.2012.04236.x – ident: e_1_2_7_30_2 doi: 10.1128/MCB.24.8.3112-3124.2004 – ident: e_1_2_7_41_2 doi: 10.1023/A:1022943419011 – ident: e_1_2_7_6_2 doi: 10.1128/MCB.18.3.1379 – ident: e_1_2_7_33_2 doi: 10.1111/j.1464-410X.2009.08538.x – ident: e_1_2_7_5_2 doi: 10.1101/gad.1212704 – ident: e_1_2_7_42_2 doi: 10.1158/0008-5472.CAN-07-0881 – ident: e_1_2_7_44_2 doi: 10.1074/jbc.M512218200 – ident: e_1_2_7_24_2 doi: 10.4111/kju.2011.52.7.466 |
| SSID | ssj0014665 |
| Score | 2.275695 |
| Snippet | What's known on the subject? and What does the study add?
A few published studies investigating single or various PI3K/AKT/mTOR signalling components have... What's known on the subject? and What does the study add? A few published studies investigating single or various PI3K/AKT/mTOR signalling components have... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | E1237 |
| SubjectTerms | 1-Phosphatidylinositol 3-kinase 4E‐BP1 Adult Aged Aged, 80 and over AKT AKT protein AKT1 AKT1 protein bladder cancer Carcinoma, Transitional Cell - genetics Carcinoma, Transitional Cell - metabolism Carcinoma, Transitional Cell - pathology Chemotherapy Class I Phosphatidylinositol 3-Kinases DNA, Neoplasm - genetics Extracellular signal-regulated kinase Female Fibroblast growth factor receptor 3 Fibroblast growth factor receptors Follow-Up Studies Humans Immunohistochemistry Initiation factors Kinases Male Middle Aged mTOR Mutation Oncogenes p70S6K p85aPI3K Phosphatidylinositol 3-Kinases - genetics Phosphatidylinositol 3-Kinases - metabolism phosphoinositides PIK3CA Polymerase Chain Reaction Prognosis Proto-Oncogene Proteins c-akt - genetics Proto-Oncogene Proteins c-akt - metabolism Regulatory subunits Retrospective Studies Signal Transduction Studies Survival Survival analysis thymoma TOR protein TOR Serine-Threonine Kinases - genetics TOR Serine-Threonine Kinases - metabolism Tumorigenesis UCS Urinary bladder Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - metabolism Urinary Bladder Neoplasms - pathology urothelial carcinoma urothelium |
| Title | A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3‐kinase/v‐akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2012.11569.x https://www.ncbi.nlm.nih.gov/pubmed/23107319 https://www.proquest.com/docview/1767946109 https://www.proquest.com/docview/1273128236 https://www.proquest.com/docview/1285096220 |
| Volume | 110 |
| WOSCitedRecordID | wos000315029700075&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1464-410X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014665 issn: 1464-4096 databaseCode: DRFUL dateStart: 19990101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZgixCX8oaFUg0SBziETZyH7WN5rHiUUlVdtLfIThw16iapsruFvfET-Htc-SXMJNlICwhViEMkK_E4jjyefInH38fYE-WmmeKhdCIjfCeQgcE4qKzjmgwdynCjGzmgT_vi4EBOp-qwy3-ivTAtP0T_w41mRhOvaYJrM_91kgdO4LlTytDieD6M1HPEk1sc3TgcsK1XR-PJfr-mEESNsGRrhch9M6_nj21tvqx-Q6CbgLZ5I42v_89nucG2O1wKe60j3WSXbHmLXf3QrbzfZt_3gLLPa3vSZrxDThtLqoauOOlIB0CXKRRrvV1Y05XDogKEmXD41n8_Qkw5Ko4_HsHTs5NqjkdeNmljqQX_x9dvp3mpSY4Li_p0AQWtBVi0XhVVoYESkmdQlUmFbm9HhS6K5jcNtPnsUGVAgu7FCvv8DEhs-bNeQV6CmVGArWFZ04YzNJlBQiJKJbZ6h03Gr49fvnE6WQgnCZRQTkqcf4JLGxgjUmVNFuJnEZcecQPazMjUhIGfZa7UhqfcEqF_4Fr0OhGlUer6d9mgrEp7n0EmI89KVwiJVXxfK4klI0LjZZmndThkYj3-cdJxppN0xyze-HYKYhq5mEYubkYu_jJkXm951vKGXMBmZ-1icRdJ5rEnItIA8Fw1ZI_7yxgDaGFHl7ZaYh3EoIgzuB_9rY4kph_O3SG717pv3zHC-NgC3kE0XnrhHscv3k2a4oN_tnzIrtH5NkNohw0W9dI-YleS80U-r3fZZTGVu91M_glwvUmF |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLbQhoCXcWeFAQeJB3gIzcWJncdxqTbWlWlqUd8iO3G0aE0ypS3QN34Cf49XfgnnJGmkAkIT4iGSlfo4rvz55MQ-_j7Gnod2koauL61AC8_ikmv0g6GxbJ0ioLSrVS0H9HEoRiM5nYYnrRwQnYVp-CG6BTeaGbW_pglOC9K_znJucceeUoqWi_f9IHyFAeU2R1Qh3Lffng4mw25TgQe1smRjhaH7ZmLPH9vafFv9FoJuRrT1K2lw87_-mVtsp41MYb-B0m12xRR32LXjdu_9Lvu-D5R_XpmzJucdMjpaUtaExXFLOwCqSCBfK-7CmrAcFiVgoAknh95RH6PKfj7-cAovLs7KOV5ZUSeOJQa8H1-_nWeFIkEuLKrzBeS0G2DQepWXuQJKSZ5BWcQlAt_0c5Xn9UINNBntUKZAku75Cvv8Ekhu-bNaQVaAnpGLrWBZ0ZEzNJlBTDJKBbZ6j00G78ZvDqxWGMKKeShCKyHWP-FKw7UWSWh06uOHkSsdYgc0qZaJ9rmXprZU2k1cQ5T-3DaIOxEkQWJ799lWURZml0EqA8dIWwiJVTxPhRJLWvjaSVNHKb_HxBoAUdyyppN4xyza-HriEY1cRCMX1SMXfekxp7O8aJhDLmGzt8ZY1PqSeeSIgFQAHDvssWfdz-gFaGtHFaZcYh2MQjHScL3gb3Ukcf24rt1jDxr8dh2jKB9bwCeIGqaX7nH0-v2kLj78Z8un7PrB-HgYDQ9HR4_YDarT5Avtsa1FtTSP2dX40yKbV0_aCf0TXJpMjQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZQF6248GYpLDBIHOAQmocTO8eFpWLZUqrVFvUW2YmtrbZJqj526Y2fwN_jyi9hJkkrFRBaIQ6RrMTjOPJ48iUefx9jL2I3s7EfSifSInC45BrjYGwcV1t0KO1rVckBfe6Jfl-ORvGgkQOivTA1P8TmhxvNjCpe0wQ308z-Osu5wz13RClaPp4Po_g1AsodTpoyLbZzeNId9jaLCjyqlCVrK4Tu24k9f2xr-231GwTdRrTVK6l7678-zG12s0GmcFC70h12zRR32e7HZu39Hvt-AJR_PjNndc47jGlrSVkRFqcN7QCoIoN8rbgLa8JyWJSAQBMGR8FxB1FlJz_9dAIvp2flHI9xUSWOZQaCH1-_nY8LRYJcWFTnC8hpNcCg9SovcwWUkjyBskhLdHzTyVWeVz9qoM5oh9ICSbrnK-zzKyC55Uu1gnEBekIhdgbLGW05Q5MJpCSjVGCr99mw--707XunEYZwUh6L2MmI9U_40nCtRRYbbUP8MPKlR-yAxmqZ6ZAH1rpSaT_zDVH6c9eg34koizI3eMBaRVmYhwysjDwjXSEkVgkCFUssaRFqz1pPqbDNxNoBkrRhTSfxjkmy9fXEExq5hEYuqUYu-dJm3sZyWjOHXMFmf-1jSRNL5oknIlIB8Ny4zZ5vLmMUoKUdVZhyiXUQhSLS8IPob3Ukcf34vttme7X_bjpGKB9bwDuIyk2v3OPkzYdhVXz0z5bP2O7gsJv0jvrHj9kNqlKnC-2z1mK2NE_Y9fRiMZ7Pnjbz-Sd2DkwI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+comprehensive+immunohistochemical+and+molecular+approach+to+the+PI3K%2FAKT%2FmTOR+%28phosphoinositide+3-kinase%2Fv-akt+murine+thymoma+viral+oncogene%2Fmammalian+target+of+rapamycin%29+pathway+in+bladder+urothelial+carcinoma&rft.jtitle=BJU+international&rft.au=Korkolopoulou%2C+Penelope&rft.au=Levidou%2C+Georgia&rft.au=Trigka%2C+Eleni-Andriana&rft.au=Prekete%2C+Niki&rft.date=2012-12-01&rft.eissn=1464-410X&rft.volume=110&rft.issue=11+Pt+C&rft.spage=E1237&rft_id=info:doi/10.1111%2Fj.1464-410X.2012.11569.x&rft_id=info%3Apmid%2F23107319&rft.externalDocID=23107319 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon |